Cellular Therapies for the Treatment and Prevention of SARS-CoV-2 Infection

Cellular Therapies for the Treatment and Prevention of SARS-CoV-2 Infection

Patients with blood disorders who are immune suppressed are at increased risk for infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus. Sequelae of infection can include severe respiratorydisease and/or prolonged duration of viral shedding. Cellular therapies may pro...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2022-07, Vol.140 (3), p.208-221
Hauptverfasser: Conway, Susan R., Keller, Michael D, Bollard, Catherine M
Format: Artikel
Sprache:eng
Schlagworte:
cell therapy
COVID-19
Covid-19 and the Hematologist
mesenchymal stromal cell
virus-specific T cell
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 221
container_issue 3
container_start_page 208
container_title Blood
container_volume 140
creator Conway, Susan R.
Keller, Michael D
Bollard, Catherine M
description Patients with blood disorders who are immune suppressed are at increased risk for infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus. Sequelae of infection can include severe respiratorydisease and/or prolonged duration of viral shedding. Cellular therapies may protect these vulnerable patients by providing anti-viral cellular immunity and/or immune modulation. In this recent Review of the field, phase I/II trials evaluating adoptive cellular therapies with virus-specific T cells or natural killer cells are described along with trials evaluating the safety, feasibility, and preliminary efficacy of immune modulating cellular therapies including regulatory T cells and mesenchymal stromal cells. In addition, the immunological basis for these therapies is discussed.
doi_str_mv 10.1182/blood.2021012249
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8896869</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497122003202</els_id><sourcerecordid>2636146391</sourcerecordid><originalsourceid>FETCH-LOGICAL-c447t-65ee13b37e5e9139c12176624f973cf8aeb849c1fee95d0c7aa1cebf087472873</originalsourceid><addsrcrecordid>eNp1UU1vEzEQtRAVDaF3TshHLlv8tf7ggFRFUCoqtaJpr5bXOyZGm3WwN5H67-s2pS0HTjOaefPm6T2E3lNyTKlmn7ohpf6YEUYJZUyYV2hGW6YbQhh5jWaEENkIo-ghelvKb0Ko4Kx9gw55ywSRyszQjwUMw3ZwGS9XkN0mQsEhZTytAC8zuGkN44Td2OPLDLvaxzTiFPDVyc-rZpFuGobPxgD-fv4OHQQ3FDh6rHN0_e3rcvG9Ob84PVucnDdeCDU1sgWgvOMKWjCUG08ZVVIyEYziPmgHnRZ1GgBM2xOvnKMeukC0Eoppxefoy553s-3W0PuqKrvBbnJcu3xrk4v2380YV_ZX2lmtjdTSVIKPjwQ5_dlCmew6Fl-NcCOkbbFMckmF5FXdHJE91OdUSobw9IYSe5-BfcjAPmdQTz68lPd08Nf0Cvi8B0A1aRch2-IjjB76mKuTtk_x_-x3wTKWww</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2636146391</pqid></control><display><type>article</type><title>Cellular Therapies for the Treatment and Prevention of SARS-CoV-2 Infection</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Conway, Susan R. ; Keller, Michael D ; Bollard, Catherine M</creator><creatorcontrib>Conway, Susan R. ; Keller, Michael D ; Bollard, Catherine M</creatorcontrib><description>Patients with blood disorders who are immune suppressed are at increased risk for infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus. Sequelae of infection can include severe respiratorydisease and/or prolonged duration of viral shedding. Cellular therapies may protect these vulnerable patients by providing anti-viral cellular immunity and/or immune modulation. In this recent Review of the field, phase I/II trials evaluating adoptive cellular therapies with virus-specific T cells or natural killer cells are described along with trials evaluating the safety, feasibility, and preliminary efficacy of immune modulating cellular therapies including regulatory T cells and mesenchymal stromal cells. In addition, the immunological basis for these therapies is discussed.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood.2021012249</identifier><identifier>PMID: 35240679</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>cell therapy ; COVID-19 ; Covid-19 and the Hematologist ; mesenchymal stromal cell ; virus-specific T cell</subject><ispartof>Blood, 2022-07, Vol.140 (3), p.208-221</ispartof><rights>2022 American Society of Hematology</rights><rights>Copyright © 2022 American Society of Hematology.</rights><rights>Copyright © 2022 American Society of Hematology. All rights reserved. 2022 American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c447t-65ee13b37e5e9139c12176624f973cf8aeb849c1fee95d0c7aa1cebf087472873</citedby><cites>FETCH-LOGICAL-c447t-65ee13b37e5e9139c12176624f973cf8aeb849c1fee95d0c7aa1cebf087472873</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35240679$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Conway, Susan R.</creatorcontrib><creatorcontrib>Keller, Michael D</creatorcontrib><creatorcontrib>Bollard, Catherine M</creatorcontrib><title>Cellular Therapies for the Treatment and Prevention of SARS-CoV-2 Infection</title><title>Blood</title><addtitle>Blood</addtitle><description>Patients with blood disorders who are immune suppressed are at increased risk for infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus. Sequelae of infection can include severe respiratorydisease and/or prolonged duration of viral shedding. Cellular therapies may protect these vulnerable patients by providing anti-viral cellular immunity and/or immune modulation. In this recent Review of the field, phase I/II trials evaluating adoptive cellular therapies with virus-specific T cells or natural killer cells are described along with trials evaluating the safety, feasibility, and preliminary efficacy of immune modulating cellular therapies including regulatory T cells and mesenchymal stromal cells. In addition, the immunological basis for these therapies is discussed.</description><subject>cell therapy</subject><subject>COVID-19</subject><subject>Covid-19 and the Hematologist</subject><subject>mesenchymal stromal cell</subject><subject>virus-specific T cell</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp1UU1vEzEQtRAVDaF3TshHLlv8tf7ggFRFUCoqtaJpr5bXOyZGm3WwN5H67-s2pS0HTjOaefPm6T2E3lNyTKlmn7ohpf6YEUYJZUyYV2hGW6YbQhh5jWaEENkIo-ghelvKb0Ko4Kx9gw55ywSRyszQjwUMw3ZwGS9XkN0mQsEhZTytAC8zuGkN44Td2OPLDLvaxzTiFPDVyc-rZpFuGobPxgD-fv4OHQQ3FDh6rHN0_e3rcvG9Ob84PVucnDdeCDU1sgWgvOMKWjCUG08ZVVIyEYziPmgHnRZ1GgBM2xOvnKMeukC0Eoppxefoy553s-3W0PuqKrvBbnJcu3xrk4v2380YV_ZX2lmtjdTSVIKPjwQ5_dlCmew6Fl-NcCOkbbFMckmF5FXdHJE91OdUSobw9IYSe5-BfcjAPmdQTz68lPd08Nf0Cvi8B0A1aRch2-IjjB76mKuTtk_x_-x3wTKWww</recordid><startdate>20220721</startdate><enddate>20220721</enddate><creator>Conway, Susan R.</creator><creator>Keller, Michael D</creator><creator>Bollard, Catherine M</creator><general>Elsevier Inc</general><general>American Society of Hematology</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220721</creationdate><title>Cellular Therapies for the Treatment and Prevention of SARS-CoV-2 Infection</title><author>Conway, Susan R. ; Keller, Michael D ; Bollard, Catherine M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c447t-65ee13b37e5e9139c12176624f973cf8aeb849c1fee95d0c7aa1cebf087472873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>cell therapy</topic><topic>COVID-19</topic><topic>Covid-19 and the Hematologist</topic><topic>mesenchymal stromal cell</topic><topic>virus-specific T cell</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Conway, Susan R.</creatorcontrib><creatorcontrib>Keller, Michael D</creatorcontrib><creatorcontrib>Bollard, Catherine M</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Conway, Susan R.</au><au>Keller, Michael D</au><au>Bollard, Catherine M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cellular Therapies for the Treatment and Prevention of SARS-CoV-2 Infection</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2022-07-21</date><risdate>2022</risdate><volume>140</volume><issue>3</issue><spage>208</spage><epage>221</epage><pages>208-221</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>Patients with blood disorders who are immune suppressed are at increased risk for infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus. Sequelae of infection can include severe respiratorydisease and/or prolonged duration of viral shedding. Cellular therapies may protect these vulnerable patients by providing anti-viral cellular immunity and/or immune modulation. In this recent Review of the field, phase I/II trials evaluating adoptive cellular therapies with virus-specific T cells or natural killer cells are described along with trials evaluating the safety, feasibility, and preliminary efficacy of immune modulating cellular therapies including regulatory T cells and mesenchymal stromal cells. In addition, the immunological basis for these therapies is discussed.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>35240679</pmid><doi>10.1182/blood.2021012249</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2022-07, Vol.140 (3), p.208-221
issn 0006-4971
1528-0020
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8896869
source EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects cell therapy
COVID-19
Covid-19 and the Hematologist
mesenchymal stromal cell
virus-specific T cell
title Cellular Therapies for the Treatment and Prevention of SARS-CoV-2 Infection
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T03%3A42%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cellular%20Therapies%20for%20the%20Treatment%20and%20Prevention%20of%20SARS-CoV-2%20Infection&rft.jtitle=Blood&rft.au=Conway,%20Susan%20R.&rft.date=2022-07-21&rft.volume=140&rft.issue=3&rft.spage=208&rft.epage=221&rft.pages=208-221&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood.2021012249&rft_dat=%3Cproquest_pubme%3E2636146391%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2636146391&rft_id=info:pmid/35240679&rft_els_id=S0006497122003202&rfr_iscdi=true